SINGAPORE /PRNewswire/
-- Mundipharma, a multinational pharmaceutical leader in pain
management, will present the abstract of its first and largest
cross-sectional evaluation of patients' perspectives on cancer pain
management at the American Society of Clinical Oncology
(ASCO), Chicago,
Illinois, from 29 May to 2 June
2015.
The
Mundipharma-sponsored ACHEON[[1]] study poster,
summarizing data collected from 1,190 patients across 10 Asian
countries[[2]] found a significant impact of cancer
pain on a patient's quality of life, employment and self-reliance,
highlighting the need to develop more effective management
practices for cancer pain that will require collaborative efforts
from institutional, social and regulatory organisations.
Dr. Jin Seok
Ahn - Medical Oncologist, Samsung Medical
Center, Seoul,
Republic of Korea, commented:"Cancer-related pain is
complex and debilitating condition that creates a significant
socioeconomic burden for patients across Asia.
The data from the ACHEON survey confirms the need for collaboration
in order to make effective and efficient pain management available
in order to help patients enhance their quality of life."
53 per
cent of respondents attributed their pain from cancer, while 18 per
cent related it back to cancer-related therapy. Unfortunately, 40
per cent of patients have reported that their pain treatment was
inadequate to control their pain on at least one occasion in the
past.
Of the
1,059 patients receiving treatments for their cancer pain, only 286
of these patients were receiving opioids. 84 per cent of patients
had never been referred to a pain clinic and only half of the
patients had had their pain assessed according to a scale and only
6 per cent had been treated by pain specialists.
Raman
Singh, President, Asia
Pacific, Latin
America, Middle
East, and Africa,
commented: "The ACHEON survey results have
confirmed our findings in relation to the gaps between the
patient's access to accurate treatment and the physician's pain
management practice from an Asian perspective."
"At Mundipharma, we recognize the importance of timely access
to healthcare and we consider it our responsibility to ensure that
patients get the best possible opportunity to treat pain
effectively. We are continuously invested in stakeholder
education through diverse informational programs, including our
regional Pain Forums, Pain Focus website, an educational online
portal for healthcare professionals and patients, as well as our
Pain Assessment via Pain Scale initiatives, and we look forward to
increasing upon our initiatives throughout Asia."
For further information please contact:
Stephenie
Vasko
Communications Director - Asia, Latin
America & Middle
East
PH +65-6303-9732
[email protected]
www.mundipharma.com.sg
About ACHEON
The
non-interventional, anonymous, non-biased ACHEON survey was the
first and largest cross-sectional evaluation of physicians' and
patients' perspectives on cancer and non-cancer pain management in
10 Asian
countries/regions (Mainland China, Hong
Kong, Indonesia,
Korea, Malaysia, Philippines, Singapore, Taiwan,Thailand and Vietnam).
About Mundipharma
The
Mundipharma network of independent associated companies consists of
privately owned companies and joint ventures covering the world's
pharmaceutical markets. These companies are committed to bringing
to patients the benefits of pioneering treatment options in the
core therapy areas of oncology, pain, respiratory and rheumatoid
arthritis.
www.mundipharma.com.sg
[[1]]
Current Practices of Cancer
and Chronic Non-Cancer Pain Management: A Pan-Asian Study (ACHEON
Study)
[[2]]
10 Asian countries
and regions mainland
China, Hong Kong, Indonesia, Republic of Korea, Malaysia,
Philippines, Singapore, Taiwan, Thailand and Vietnam
Logo
- http://photos.prnasia.com/prnh/20150302/8521501264LOGO